retatrutide dosing trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Reta Titration Schedule : r/Retatrutide
Description
Prakash, A., & Goa, K
A.AravindL.RaoA
8.7 g, 95% CI 29.6 to 12.24 g, p = 0.479)
Actual settlements will depend on individual case factors
Ongoing monitoring of kidney function and overall health is critical to ensure the treatment remains both safe and effective
